4 recruiting, 3 active not recruiting, 2 not yet recruiting, 1 completed. 12 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Recruiting 4, Active not recruiting 3, Not yet recruiting 2, Completed 1, Enrolling by invitation 1, Terminated 1 |
Follow IgA Nephropathy (IgAN): new trials by email Literature Review of IgA Nephropathy (IgAN) trials Research Report on IgA Nephropathy (IgAN)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SLN12140 in Adult Participants With IgA Nephropathy in China SLN12140, Placebo - IgA Nephropathy (IgAN) | Phase 2 | Not yet recruiting | Linno Pharmaceuticals, Inc. | 48 | 2026-05-29 | 2026-04-28 |
| Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases EVER001 - Minimal Change Disease (MCD), IgA Nephropathy (IgAN) | Phase 2 | Recruiting | Everest Medicines (China) Co.,Ltd. | 45 | 2026-05-20 | 2026-08-05 |
| A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy RG002C0106, placebo subcutaneous administration - IgA Nephropathy (IgAN) | Phase 2 | Active not recruiting | Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd. | 30 | 2025-09-08 | 2026-10-13 |
| Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease ADX-038 Dose Level 2, ADX-038 Dose Level 1, ADX-038 Dose Level 3 - IgAN, C3G | Phase 2 | Recruiting | ADARx Pharmaceuticals, Inc. | 85 | 2025-08-28 | 2026-11-18 |
| A Study to Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in Primary IgA Nephropathy HSK39297 200mgQD, HSK39297 300mgQD - IgA Nephropathy (IgAN) | Phase 2 | Recruiting | Haisco Pharmaceutical Group Co., Ltd. | 73 | 2025-08-25 | 2026-06-01 |
| Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN) Avacopan, Prednisone, Methylprednisolone (drug) - IgA Nephropathy (IgAN) | Phase 2 | Recruiting | Mayo Clinic | 16 | 2025-06-09 | 2026-10-09 |
| A Study of SGB-9768 in Patients With Complement-mediated Kidney Diseases SGB-9768 - IgA Nephropathy (IgAN), C3 Glomerulopathy | Phase 2 | Active not recruiting | Suzhou Sanegene Bio Inc. | 45 | 2025-06-06 | 2026-09-04 |
| Monthly Dosing of Atacicept in IgAN Atacicept - IgA Nephropathy (IgAN), Berger Disease | Phase 2 | Active not recruiting | Vera Therapeutics, Inc. | 90 | 2025-05-29 | 2026-11-13 |
| Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN) MY008211A tablets, MY008211A tablets matched placebo - IgA Nephropathy (IgAN) | Phase 2 | Not yet recruiting | Wuhan Createrna Science and Technology Co., Ltd | 72 | 2024-12-31 | 2024-11-18 |
| A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept Atacicept 150 mg - IgA Nephropathy (IgAN), Renal and Urinary Disorders | Phase 2 | Enrolling by invitation | Vera Therapeutics, Inc. | 750 | 2024-12-01 | 2026-06-22 |
| Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN Placebo, HSK39297 50mgBID, HSK39297 100mgBID - IgA Nephropathy (IgAN) | Phase 2 | Completed | Haisco Pharmaceutical Group Co., Ltd. | 87 | 2024-10-12 | 2026-05-28 |
| A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN) Placebo, Cemdisiran - IgA Nephropathy (IgAN), Berger Disease | Phase 2 | Terminated | Alnylam Pharmaceuticals | 31 | 2019-09-30 | 2024-08-09 |
Glomerulonephritis, IGA (12) · Glomerulosclerosis, Focal Segmental (1) · Kidney Diseases (1) · Nephrosis, Lipoid (1) · Urologic Diseases (1)
Autoimmune Diseases (12) · Female Urogenital Diseases (12) · Female Urogenital Diseases and Pregnancy Complications (12) · Glomerulonephritis (12) · Immune System Diseases (12) · Male Urogenital Diseases (12) · Nephritis (12) · Urogenital Diseases (12) · Kidney Diseases (11) · Urologic Diseases (11) · Nephrosis (1)
TACI receptor-IgG Fc fragment fusion protein (2) · Methylprednisolone (1) · Pharmaceutical Preparations (1) · Prednisolone (1) · Prednisone (1) · avacopan (1)
Haisco Pharmaceutical Group Co., Ltd. (2) · Vera Therapeutics, Inc. (2) · ADARx Pharmaceuticals, Inc. (1) · Alnylam Pharmaceuticals (1) · Everest Medicines (China) Co.,Ltd. (1) · Linno Pharmaceuticals, Inc. (1) · Mayo Clinic (1) · Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd. (1) · Suzhou Sanegene Bio Inc. (1) · Wuhan Createrna Science and Technology Co., Ltd (1)
China (7) · United States (4) · Spain (2) · Taiwan (2) · United Kingdom (2) · Australia (1) · Canada (1) · France (1) · Hong Kong (1) · Italy (1) · Malaysia (1) · Philippines (1) · Singapore (1) · South Korea (1) · Sweden (1)
Arezoo Mirad, MD (1) · Eric Michael, MD (1) · Fernando Fervenza, MD (1) · Hong Zhang, PH.D. (1) · Nabeel Aslam, MD (1) · Zeeshan Khawaja (1)
2018 (1)